Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial

被引:358
作者
Abou-Alfa, Ghassan K. [1 ]
Johnson, Philip [3 ]
Knox, Jennifer J. [4 ]
Capanu, Marinela [2 ]
Davidenko, Irina [5 ]
Lacava, Juan [6 ]
Leung, Thomas [7 ]
Gansukh, Bolorsukh [1 ]
Saltz, Leonard B. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA
[3] Univ Birmingham, Sch Canc Sci, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England
[4] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada
[5] Krasnodar City Oncol Ctr, Krasnodar, Russia
[6] Oncol Serv, Unidad Oncol Neuquen, Neuquen, Argentina
[7] Hong Kong Sanat & Hosp, Comprehens Oncol Ctr, Hong Kong, Hong Kong, Peoples R China
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2010年 / 304卷 / 19期
关键词
SOLID TUMORS; PHASE-III; RAF/MEK/ERK; BAY-43-9006; COMBINATION; RESISTANCE; SURVIVAL; THERAPY; KINASE;
D O I
10.1001/jama.2010.1672
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context In a randomized phase 3 trial, 400 mg of sorafenib twice daily prolonged overall survival of patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh A disease. In a phase 1 study, sorafenib combined with doxorubicin, 60 mg/m(2), was well tolerated by patients with refractory solid tumors. The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial. Objective To evaluate the efficacy and safety of doxorubicin plus sorafenib compared with doxorubicin alone in patients with advanced HCC and Child-Pugh A disease. Design, Setting, and Patients In a double-blind phase 2 multinational study, conducted from April 2005 to October 2006, 96 patients (76% male; median age, 65 years [range, 38-82 years]) with advanced HCC, Eastern Cooperative Oncology Group performance status 0 to 2, Child-Pugh A status, and no prior systemic therapy were randomly assigned to receive 60 mg/m2 of doxorubicin intravenously every 21 days plus either 400 mg of sorafenib or placebo orally twice a day. The date of the last patient's follow-up was April 2008. Main Outcome Measure Time to progression as determined by independent review. Results Following complete accrual, an unplanned early analysis for efficacy was performed by the independent data monitoring committee, so the trial was halted. The 2 patients remaining in the placebo group at that time were offered sorafenib. Based on 51 progressions, 63 deaths, and 70 events for progression-free survival, median time to progression was 6.4 months in the sorafenib-doxorubicin group (95% confidence interval [CI], 4.8-9.2), and 2.8 months (95% CI, 1.6-5) in the doxorubicin-placebo monotherapy group (P=.02). Median overall survival was 13.7 months (95% CI, 8.9-not reached) and 6.5 months (95% CI, 4.5-9.9; P=.006), and progression-free survival was 6.0 months (95% CI, 4.6-8.6) and 2.7 months (95% CI, 1.4-2.8) in these groups, respectively (P=.006). Toxicity profiles were similar to those for the single agents. Conclusions Among patients with advanced HCC, treatment with sorafenib plus doxorubicin compared with doxorubicin monotherapy resulted in greater median time to progression, overall survival, and progression-free survival. The degree to which this improvement may represent synergism between sorafenib and doxorubicin remains to be defined. The combination of sorafenib and doxorubicin is not yet indicated for routine clinical use.
引用
收藏
页码:2154 / 2160
页数:7
相关论文
共 23 条
[1]   Hepatocellular carcinoma: Molecular biology and therapy [J].
Abou-Alfa, Ghassan K. .
SEMINARS IN ONCOLOGY, 2006, 33 (06) :S79-S83
[2]   Phase II study of sorafenib in patients with advanced hepatocellular carcinoma [J].
Abou-Alfa, Ghassan K. ;
Schwartz, Lawrence ;
Ricci, Sergio ;
Amadori, Dino ;
Santoro, Armando ;
Figer, Arie ;
De Greve, Jacques ;
Douillard, Jean-Yves ;
Lathia, Chetan ;
Schwartz, Brian ;
Taylor, Ian ;
Moscovici, Marius ;
Saltz, Leonard B. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4293-4300
[3]   Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1 [J].
Alavi, Alireza S. ;
Acevedo, Lisette ;
Min, Wang ;
Cheresh, David A. .
CANCER RESEARCH, 2007, 67 (06) :2766-2772
[4]   Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin [J].
Gish, Robert G. ;
Porta, Camillo ;
Lazar, Lucian ;
Ruff, Paul ;
Feld, Ronald ;
Croitoru, Adina ;
Feun, Lynn ;
Jeziorski, Krzysztof ;
Leighton, John ;
Gallo, Jose ;
Kennealey, Gerard T. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (21) :3069-3075
[5]   A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].
GRAY, RJ .
ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154
[6]  
IHDE DC, 1977, CANCER TREAT REP, V61, P1385
[7]  
JOHNSON PJ, 1978, LANCET, V1, P1006
[8]   Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib [J].
Lacouture, Mario E. ;
Wu, Shenhong ;
Robert, Caroline ;
Atkins, Michael B. ;
Kong, Heidi H. ;
Guitart, Joan ;
Garbe, Claus ;
Hauschild, Axel ;
Puzanov, Igor ;
Alexandrescu, Doru T. ;
Anderson, Roger T. ;
Wood, Laura ;
Dutcher, Janice P. .
ONCOLOGIST, 2008, 13 (09) :1001-1011
[9]   Sorafenib in advanced hepatocellular carcinoma [J].
Llovet, Josep M. ;
Ricci, Sergio ;
Mazzaferro, Vincenzo ;
Hilgard, Philip ;
Gane, Edward ;
Blanc, Jean-Frederic ;
Cosme de Oliveira, Andre ;
Santoro, Armando ;
Raoul, Jean-Luc ;
Forner, Alejandro ;
Schwartz, Myron ;
Porta, Camillo ;
Zeuzem, Stefan ;
Bolondi, Luigi ;
Greten, Tim F. ;
Galle, Peter R. ;
Seitz, Jean-Francois ;
Borbath, Ivan ;
Haussinger, Dieter ;
Giannaris, Tom ;
Shan, Minghua ;
Moscovici, Marius ;
Voliotis, Dimitris ;
Bruix, Jordi .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :378-390
[10]   Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance [J].
McCubrey, James A. ;
Steelman, Linda S. ;
Abrams, Steven L. ;
Lee, John T. ;
Chang, Fumin ;
Bertrand, Fred E. ;
Navolanic, Patrick M. ;
Terrian, David M. ;
Franklin, Richard A. ;
D'Assoro, Antonio B. ;
Salisbury, Jeffrey L. ;
Mazzarino, Maria Clorinda ;
Stivala, Franca ;
Libra, Massimo .
ADVANCES IN ENZYME REGULATION, VOL 46, PROCEEDINGS, 2006, 46 :249-279